Myriad Genetics (MYGN) Change in Accured Expenses (2009 - 2026)

Myriad Genetics has disclosed Change in Accured Expenses across 18 years of filings, most recently posting -$7.4 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 40.32% year-over-year to -$7.4 million; the TTM figure through Mar 2026 stood at -$22.5 million (up 42.01% YoY), while the FY2025 annual figure was -$27.5 million, up 32.93% from the prior year.
• Change in Accured Expenses retreated to -$7.4 million in Q1 2026, from -$6.7 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for MYGN reached as high as $71.9 million in Q2 2023 and fell as low as -$59.4 million in Q4 2023.
• The 5-year median for Change in Accured Expenses is -$6.7 million (2025), against an average of -$7.9 million.
• The widest YoY moves for Change in Accured Expenses: up 4340.0% in 2023, down 2021.43% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at -$2.8 million in 2022, then tumbled by 2021.43% to -$59.4 million in 2023, then soared by 53.7% to -$27.5 million in 2024, then soared by 75.64% to -$6.7 million in 2025, then declined by 10.45% to -$7.4 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$7.4 million, -$6.7 million, and $8.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.